Abstract
Objectives To present the relevant information for the education of patients with B-cell non-Hodgkin’s lymphoma (NHL) who are about to undergo radioimmunotherapy (RIT) with yttrium 90 ( 90Y) ibritumomab tiuxetan. Data sources Published clinical trials of 90Y ibritumomab tiuxetan and secondary literature on radioimmunotherapy and NHL. Conclusion RIT is an emerging therapeutic option for patients with B-cell NHL and promises to become more prevalent in clinical use. Patients need to understand the rationale for and schedule of treatments with this regimen and the necessary ongoing laboratory tests for monitoring myelosuppression, as well as possible adverse events that might occur after treatment. Implications for nursing practice Nursing professionals should be aware of the logistics of the ibritumomab tiuxetan regimen and with the data associated with it to educate patients and facilitate patient understanding and expectations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
